PROCEPT BioRobotics (PRCT) Current Deferred Revenue (2020 - 2026)

PROCEPT BioRobotics (PRCT) has reported Current Deferred Revenue for 7 consecutive years, with $14.1 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Current Deferred Revenue rose 42.46% year-over-year to $14.1 million in Q2 2026; TTM through Jun 2026 was $14.1 million, a 42.46% increase from a year earlier, with the FY2025 full-year figure at $13.0 million, up 36.41% from the prior year.
• Current Deferred Revenue was $14.1 million for Q2 2026 at PROCEPT BioRobotics, up from $13.7 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $14.1 million in Q2 2026 and troughed at $1.4 million in Q1 2022.
• A 5-year average of $7.2 million and a median of $6.2 million in 2024 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue surged 188.23% in 2023 and jumped 33.5% in 2025, its largest moves.
• Over 5 years, Current Deferred Revenue stood at $2.9 million in 2022, then jumped by 98.11% to $5.7 million in 2023, then jumped by 69.11% to $9.6 million in 2024, then soared by 36.41% to $13.0 million in 2025, then increased by 7.97% to $14.1 million in 2026.
• The last three Current Deferred Revenue figures came in at $14.1 million (Q2 2026), $13.7 million (Q1 2026), and $13.0 million (Q4 2025), per Business Quant data.